Nasal and pulmonary drug delivery systems

Bibliography

• DAVIS SS: Delivery of peptide and non-peptide drugs through the respiratory tract. Pharm. Sci. Technol. Today (1999) 2:450–456.
   PubMedGoogle Scholar
• •Review on recent advances in the delivery of both peptide and non-peptide drugs to the respiratory tract. A comparison between nasal and pulmonary delivery is made.
   Google Scholar
• BEHL CR, PIMPLASKAR HK, SILENO AP, DEMEIRELES J, ROMEO VD: Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Deliv. Rev. (1998) 29:89–116.
   PubMed Web of Science ®Google Scholar
• ••Review on the feasibility evaluation of drug nasal deliveryfrom anatomical considerations to preformulation studies leading to the development of a final formulation.
   Google Scholar
• BOMMER R: Advances in nasal drug delivery technology. Pharm. Technol Eur. (1999):26–33.
   Web of Science ®Google Scholar
• •Review on some of the latest devices for liquid and dry powder formulations including preservative-free systems.
   Google Scholar
• BATTS AH, MARRIOTT C, MARTIN GP, BOND SW: The effect of some preservatives used in nasal prepara-tions on mucociliary clearance. J. Pharm. Pharmacol (1989) 41:156–159.
   PubMed Web of Science ®Google Scholar
• •This reference describes the effects of some preservatives used in multi-dose nasal preparations on mucociliary transport rate.
   Google Scholar
• ILLUM L: Drug delivery systems for nasal application. STP Pharma. (1987) 3:594–598
   Google Scholar
• •General description of the delivery systems suitable for intranasal administration of drugs.
   Google Scholar
• BEHL CR, PIMPLASKAR HK, SILENO AP et al.: Optimiza- tion of systemic nasal drug delivery with pharmaceu-tical excipients. Adv. Drug Deliv. Rev. (1998) 29:117–133.
   PubMed Web of Science ®Google Scholar
• ••This review discusses the most widely used formulationapproaches to improve drug absorption through the nasal administration route.
   Google Scholar
• DUCHENE D, TOUCHARD F, PEPPAS NA: Pharmaceutical and medical aspects of bioadhesive systems for drug administration. Drug Devel. Indust. Pharm. (1988) 14:283–318.
   Web of Science ®Google Scholar
• •This paper deeply investigates bioadhesion mechanisms, factors influencing bioadhesion phenomema, bioadhesive polymers and dosage forms.
   Google Scholar
• PERESWETOFF-MORATH L: Microspheres as nasal drug delivery systems. Adv. DrugDeliv. Rev. (1998) 29:185–194.
   PubMed Web of Science ®Google Scholar
• •Review on different types of microspheres that can be used to improve nasal absorption of drugs. Microspheres made of different materials are compared for their in vivo behavior as drug delivery also considering toxicological aspects.
   Google Scholar
• DE PONTI R, LARDINI E: Use of chemical enhancers for nasal delivery. Drug Dev. Ind. Pharm. (1991) 17(10:1419–1436.
   Google Scholar
• •This paper gives a general and widespread overview on chemical enhancers considered for nasal drug delivery.
   Google Scholar
• KOTZÉ AF, LUESSEN HL, DE BOER AG, VERHOEF JC, JUNGINGER HE: Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. Eur. J. Pharm. Sci. (1998) 7:145–151.
   Web of Science ®Google Scholar
• •This reference offers a deep experimental evaluation of chitosan as a mucoadhesive polymer suitable to be used to enhance trough transmucosal drug absorption.
   Google Scholar
• MEGGS WJ: Mechanism of allergy and chemical sensitivity. Toxicol. Ind. Health (1999) 15(3-4):331–338.
   PubMed Web of Science ®Google Scholar
• •This paper describes allergy and chemical sensitivity mechanism.
   Google Scholar
• SUONPAA J: Treatment of allergic rhinitis. Ann. Med. (1996) 28(0:17–22.
   PubMedGoogle Scholar
• •The reference describes therapeutic strategies to treat allergic rhinitis.
   Google Scholar
• KRAUSE HF: Pharmacotherapy of perennial and seasonal allergic rhinitis. Clin. Immunother. (1995) 3 (4):308–324.
   Google Scholar
• •The reference describes therapeutic strategies to treat allergic rhinitis by the use of anti-histamines, corticosteroids, decongestants, mast cell stabilisers and other agents, such as mucolytics and anticholinergics.
   Google Scholar
• LAVELLE E: Targeted mucosal delivery of drugs and vaccines. Exp. Opin. Ther. Patents (2000) 10 (2):179–190.
   Web of Science ®Google Scholar
• •This review examines the potential for targeted mucosal drug and vaccine delivery.
   Google Scholar
• JENKINS PG: Mucosal vaccine delivery. Exp. Opin. Ther. Patents (1999) 9(3):255–262.
   Web of Science ®Google Scholar
• •This reference offers a description of the recent advances on drug delivery strategies for mucosal administration of vaccines. Strengths and weaknesses of different approaches are discussed.
   Google Scholar
• McCLUSKIE MJ, DAVIS HL: Novel strategies using DNA for the induction of mucosal immunity. Grit. Rev. Immunol. (1999) 19 (4) :303–329.
   PubMed Web of Science ®Google Scholar
• •This paper describes the recent advances in vaccination strategies using DNA delivered to mucosal surfaces.
   Google Scholar
• CORNAZ AL, BURI P: Nasal mucosa as an absorption barrier. Eur. J. Pharm. Biopharm. (1994) 40(5) :261–270.
   Web of Science ®Google Scholar
• •This paper provides a detailed description of the nasal mucosal barrier: a good comprehension of the factors limiting drug permeation trough nasal mucosa can lead to the identification of effective strategies to improve intranasal absorption of drugs.
   Google Scholar
• MERKUS FWHM, VERHOEF JC, MARTTIN E et al.: Cyclodextrins in nasal drug delivery. Adv. Drug Deliv. Rev. (1999) 36:41–57.
   PubMed Web of Science ®Google Scholar
• •In the review the use of cyclodextrins in nasal drug formula-tion both as solubilising agents and absorption enhancers is discussed. It is an example of a new class of safe enhancers. A special focus is given to intranasal protein and peptide intranasal formulation.
   Google Scholar
• MARINARO M, DI TOMASO A, UZZAU S, FASANO A, DE MAGISTRIS MT: Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens. Infect. Immun. (1999) 67 (3) :1287–1291.
   PubMed Web of Science ®Google Scholar
• •This reference focuses on the possibility the use Zonula occludens toxin (ZOT) as an adjuvant to deliver soluble antigens through the nasal mucosa.
   Google Scholar
• NEWMAN SP: Optimizing delivery of drugs to the lungs. Clin. Asthma Rev. (1998) 2:123–128.
   Google Scholar
• •Review of current trends of optimising delivery devices for the effective treatment of asthma.
   Google Scholar
• Inhalation Aerosols. Hickey AJ (Ed.), Marcel Dekker, Inc., New York, USA (1996).
   Google Scholar
• ••This reference combines the physical chemistry of formula-tion with the physics of aerosol generation and aerodynamic behavior in order to better understand their therapeutic implications for inhalation aerosols.
   Google Scholar
• YU J, CHIEN YW: Pulmonary drug delivery: physiologic and mechanistic aspects. Grit. Rev. Ther. Drug Carrier Syst. (1997) 14(4):395–453.
   PubMed Web of Science ®Google Scholar
• •Presentation of numerous case studies for the pulmonary delivery of proteins and peptides.
   Google Scholar
• Inhalation Delivery of Therapeutic Proteins and Peptides. Adjei LA, Gupta PK (Eds.), Marcel Dekker, Inc., New York, USA (1997).
   Google Scholar
• ••This reference offers a comprehensive analysis of proteinand peptide delivery through the lung including a detailed description of the human respiratory tract and its impact on both local and systemic delivery of biotherapeutic and macromolecular drug systems.
   Google Scholar
• ROSS DL, GABRIO BJ: Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug carrier system. J. Aerosol Med. (1999) 12(3):151–160.
   PubMedGoogle Scholar
• •Article presents formulation implications observed in CFC-free pMDIs.
   Google Scholar
• KELLER M: Developments and trends in pulmonary drug delivery. Chimica Oggi (1998) 16: (11/12) :16–24.
   Google Scholar
• •Review of inhalation drug delivery and of the importance of its understanding for effectively dealing with pulmonary functions and diseases.
   Google Scholar
• MOBLEY JL, CHIN JE, RICHARDS IM: Glucocorticoster- oids, old and new: biological function and use in the treatment of asthma. Exp. Opin. Invest. Drugs (1996) 5 (7) :871–884.
   Google Scholar
• •Expert opinion on old and new glucocorticosteroids used in the treatment of asthma.
   Google Scholar
• PATTON JS, BUKAR J, NAGARAJAN S: Inhaled insulin. Adv. Drug Deliv. Rev. (1999) 35 (2,3):235–247.
   Google Scholar
• •A review of clinical observations from inhaled insulin studies.
   Google Scholar
• WU-PONG S, BYRON PR: Airway-to-biophase transfer of inhaled oligonucleotides. Adv. Drug Delivery Rev. (1996) 19(1):47–71.
   Web of Science ®Google Scholar
• •A review of oligonucleotide delivery to and uptake by the lung. While systemic delivery remains problematical, topical delivery appears reasonable.
   Google Scholar